The combination of two broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment.

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented yesterd...

A single dose of Lenacapavir, Teropavimab, and Zinlirvimab maintained virological suppression for 6 months in 8 of 10 people with HIV-1 highly susceptible

Most people who used the long-acting antiretroviral plus two experimental HIV antibodies maintained viral suppression for six months.

Most people who used the long-acting antiretroviral plus two experimental HIV antibodies maintained viral suppression for six months.

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral suppres...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented yesterd...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented yesterd...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented yesterd...

Lenacapavir with teropavimab and zinlirvimab 10 mg/kg or 30 mg/kg was generally well tolerated with no serious adverse events. HIV-1 suppression for at least 26 weeks is feasible with this regimen at ...

Over the last few years a number of studies aiming to cure HIV or at least achieve long-term viral suppression off antiretroviral therapy (ART) have produced tantalising results. These studies have given participants one or both of the long-acting versions of two broadly neutralising antibodies (bnAbs), 3BNC117 (teropavimab) and 10-1074 (zinlirvimab), sometimes in conjunction with immune boosting oral drugs.

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral suppression and demonstrated a favorable safety profile at 26 weeks.

High rates of virologic suppression were observed in the Phase 1b study (NCT04811040) investigating lenacapavir and two broadly neutralizing antibodies (bNAb), teropavimab (30 mg/kg) and zinlirvimab (10 or 30 mg/kg), in virologically suppressed people with HIV-1 susceptible (IC90 ≤ 2 μg/mL) to both (primary cohort, n = 20) or either (pilot cohort, n = 10) bNAb. We describe resistance analyses through Week (W) 26.MethodsPost-baseline resistance analyses were conducted at virologic failure, and exploratory resistance analyses performed for participants with virologic rebound. Low copy number genotyping methods for capsid and a 1 kb stretch of gp120 from rebound virus were developed, and phenotypic susceptibility assessed.ResultsVirologic failure was observed in 1/30 participants. This primary cohort participant had HIV RNA 155 copies/mL at W16 and developed Q67H in capsid (lenacapavir fold-change 4.7), without resistance to bNAbs; the participant resuppressed on oral antiretrovirals. Two pilot cohort participants, experienced virologic rebound at W26 (55 and 72 copies/mL) and restarted oral antiretrovirals. In exploratory analyses, neither had emergent lenacapavir resistance or altered bNAb susceptibility.ConclusionsLenacapavir, teropavimab, and zinlirvimab maintained a high rate of virologic suppression through W26, with rare emergent lenacapavir resistance and no bNAb resistance, supporting further Phase 2 evaluation.

High rates of virologic suppression were observed in the Phase 1b study (NCT04811040) investigating lenacapavir and two broadly neutralizing antibodies (bNAb), teropavimab (30 mg/kg) and zinlirvimab (10 or 30 mg/kg), in virologically suppressed people with HIV-1 susceptible (IC90 ≤2 μg/mL) to both (primary cohort, n=20) or either (pilot cohort, n=10) bNAb. We describe resistance analyses through Week (W)26.MethodsBaseline genotypic and phenotypic analyses of proviral gag and envelope DNA were performed. Post-baseline resistance analyses were conducted at virologic failure, and exploratory resistance analyses performed for participants with virologic rebound. For participants with HIV-1 RNA ≥50 to <1000 copies/mL, standard viral RNA genotyping methods were unsuccessful; therefore, low copy number genotyping methods for both capsid and a 1 kb stretch of gp120 from rebound virus were developed, and phenotypic susceptibility assessed.ResultsVirologic failure was observed in 1/30 participants through W26. This primary cohort participant had HIV-1 RNA 155 copies/mL at W16 and developed Q67H in capsid (lenacapavir fold-change 4.7), without resistance to bNAbs; the participant resuppressed on oral antiretrovirals. Two pilot cohort participants, one with baseline susceptibility to teropavimab and one to zinlirvimab, experienced virologic rebound at W26 (55 and 72 copies/mL, respectively) and restarted oral antiretrovirals per protocol. In exploratory analyses, neither had baseline or emergent lenacapavir resistance or altered bNAb susceptibility.ConclusionsLenacapavir, teropavimab, and zinlirvimab maintained a high rate of virologic suppression through W26, with a low rate of emergent lenacapavir resistance and no bNAb resistance, supporting further evaluation of this combination in Phase 2.

Onyema Ogbuagu, MBBCh, FACP, FIDSA discussed 96% virologic suppression with lenacapavir-based therapy, showing similar results to daily oral regimens.

This ongoing, randomised, blind, phase 1b proof-of-concept study conducted at 11 HIV treatment centres in the USA included adults with a plasma HIV-1 ... View article...

Un essai de phase II a évalué l’administration semestrielle du lénacapavir (LEN) associé à deux anticorps neutralisants à large spectre (bNAbs), en comparaison avec un traitement antirétroviral oral standard.

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral suppression and demonstrated a favorable safety profile at 26 weeks. Led by Joe Eron, MD, a researcher with the UNC Institute for Global Health and Infectious Diseases, the findings mark a significant milestone toward what could become the first complete long-acting HIV regimen requiring dosing only twice per year.

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented yesterd...

The combination of two broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only one of the two bNAbs.MethodsPilot study within a proof-of-concept Phase 1b study (NCT04811040).ResultsNo serious treatment-emergent adverse events occurred and 8/10 participants remained virologically suppressed at Week 26.ConclusionsMore inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment.